Enhancing adoptive T cell therapy by disrupting the SKI-SMAD2/3 axis to counteract TGF-β-mediated immunosuppression

Key Points

• Immunosuppression is significantly reduced by disrupting the SKI-SMAD2/3 axis, enhancing therapy effectiveness.
• Key evidence indicates that targeting TGF-β improved T cell responses under immunosuppressive conditions.
• Analysis involved mechanisms of adoptive T cell therapy and the SKI-SMAD2/3 signaling pathway.
• Success in this approach suggests a potential advancement for cancer treatments, highlighting a new direction in therapy.